Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Evolus (EOLS) EBITDA: 2018-2025

Historic EBITDA for Evolus (EOLS) over the last 8 years, with Sep 2025 value amounting to -$15.3 million.

  • Evolus' EBITDA rose 20.68% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.0 million, marking a year-over-year decrease of 4.44%. This contributed to the annual value of -$50.9 million for FY2024, which is 17.61% up from last year.
  • Latest data reveals that Evolus reported EBITDA of -$15.3 million as of Q3 2025, which was up 9.63% from -$16.9 million recorded in Q2 2025.
  • Evolus' 5-year EBITDA high stood at $6.4 million for Q1 2021, and its period low was -$23.5 million during Q2 2022.
  • For the 3-year period, Evolus' EBITDA averaged around -$14.9 million, with its median value being -$15.3 million (2025).
  • As far as peak fluctuations go, Evolus' EBITDA soared by 132.80% in 2021, and later tumbled by 375.02% in 2022.
  • Evolus' EBITDA (MRQ) stood at -$18.2 million in 2021, then grew by 27.75% to -$13.1 million in 2022, then grew by 11.28% to -$11.7 million in 2023, then skyrocketed by 39.86% to -$7.0 million in 2024, then plummeted by 118.00% to -$15.3 million in 2025.
  • Its EBITDA was -$15.3 million in Q3 2025, compared to -$16.9 million in Q2 2025 and -$18.8 million in Q1 2025.